Drugs
A new phase III study of the investigational vaccine Gardasil, developed by Merck & Co., Inc., has shown a 100% effectiveness in preventing high-grade cervical pre-cancers and non-invasive cervical cancers associated with human papillomavirus (HPV) types 16 and 18. The study, titled FUTURE II, involved over 12,000 women from
Drugs
Japanese researchers reported the efficacy of postoperative intratumoral chemotherapy with bleomycin for craniopharyngiomas in a 1985 study. However, the treatment had not been widely implemented until a long-term outcome and reconsideration of the treatment were conducted. H. Takahashi and colleagues from Nippon Medical School investigated the effectiveness of local bleomycin
Drugs
Genzyme Corp. has significantly expanded its global infrastructure for manufacturing and product development through four major projects in Belgium, Ireland, and the United Kingdom. The new and upgraded facilities will support the company's continued growth in the areas of antibody and protein-based medicines. The projects, which have collectively
Drugs
Celera Genomics, a business within Applera Corp., has begun a phase I clinical trial for its cathepsin S inhibitor, CRA-028129, aimed at treating psoriasis. The trial, held at the Christchurch Clinical Studies Trust in New Zealand, will involve approximately 70 healthy volunteers who will receive either CRA-028129 or a placebo.
Drugs
MIV Therapeutics, a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced the filing of landmark US and international Patent Cooperation Treaty (PCT) patent applications for its advanced "Smart" drug delivery systems. The cutting-edge technology combines nanotechnology and pharmaceutical solutions to produce nano-to-micro sized particles
Drugs
Researchers in Australia, Germany, and the United States are making significant strides in understanding and treating lymphoma, a type of cancer that affects the immune system. Three recent studies have shed light on the potential of rituximab, a monoclonal antibody therapy, in combination with other treatments. While progress is being
Drugs
ImClone Systems Incorporated and Bristol-Myers Squibb announced that ImClone Systems has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for approval of ERBITUX in the treatment of squamous cell carcinoma of the head and neck. The application seeks marketing approval for the use of
Drugs
Melanoma researchers at Generex Biotechnology Corporation have made significant strides in cancer vaccine development, publishing a pivotal paper in the Journal of Immunotherapy. The study, led by scientist Nikoletta Kallinteris, showcases a novel melanoma vaccine concept that harnesses the power of T helper cells to stimulate the immune system. This
Drugs
Researchers in the United States and Japan have reported significant advances in cancer therapy by targeting angiogenesis, a crucial process in tumor growth and metastasis. Their studies demonstrate the effectiveness of new approaches in inhibiting vascular endothelial growth factor (VEGF) and its receptors, as well as other signaling pathways involved
Drugs
Genentech, Inc., Biogen Idec, Inc., and Roche announced the filing of a supplemental biologics license application (sBLA) with the U.S. Food and Drug Administration (FDA) for an additional indication of Rituxan in previously untreated patients with intermediate grade or aggressive, CD-20-positive, B-cell, non-Hodgkin lymphoma (NHL) in combination with chemotherapy
Drugs
Genentech, Inc. (DNA), Biogen Idec, Inc. (BIIB), and Roche (SWX) have completed the filing of a supplemental biologics license application (sBLA) with the U.S. Food and Drug Administration (FDA) for an additional indication of Rituxan (Rituximab) in previously untreated patients with intermediate-grade or aggressive, CD-20-positive, B-cell, non-Hodgkin lymphoma (NHL)
Drugs
Corautus Genetics, a clinical-stage biopharmaceutical company, has reported an update on its therapeutic development program and financial results for the three and six months ended June 30, 2005. The company's GENASIS clinical trial is the largest cardiovascular study of its kind, evaluating the safety and efficacy of vascular
